NCT04520412

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)

• Status: Suspended
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,046 (estimated)
• Sponsor: Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	GV-971	Administered PO
DRUG	Placebo	Administered PO

Timeline

• Start date: 2020-10-27
• Primary completion: 2025-12-01
• Completion: 2026-10-01
• First posted: 2020-08-20
• Last updated: 2022-11-23

Locations

171 sites across 10 countries: United States, Australia, Canada, China, Czechia, France, Hong Kong, Netherlands, Poland, Taiwan

Regulatory

• FDA-regulated drug study